Mesoblast

Mesoblast Deferred Tax Liabilities

Deferred Tax Liabilities of Mesoblast (MSB.AX) as of Nov 19, 2026.

Deferred Tax Liabilities

0.00USD

Last updated:

Deferred Tax Liabilities of Mesoblast is 2022 0.00 USD. Deferred Tax Liabilities of Mesoblast was 2021 0.00 USD. It decreases by % lower compared to the previous year.

The Mesoblast Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2015
149.39 M USD
Jan 1, 2016
62.69 M USD
Jan 1, 2017
49.29 M USD
Jan 1, 2018
20.08 M USD
Jan 1, 2019
11.12 M USD
Jan 1, 2020
730,000.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
The Mesoblast Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
0.00USD—
0.00USD-100.00%
730,000.00USD-93.44%
11.12 MUSD-44.60%
20.08 MUSD-59.27%
49.29 MUSD-21.37%
62.69 MUSD-58.03%
149.39 MUSD-0.08%
149.50 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mesoblast stock

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities Mesoblast since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's Mesoblast historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Mesoblast

All Key Metrics — Mesoblast